ASH Highlights

flipper_slider

Editor's Choice

Dr Jean-Jacques Kiladjian summarises the unmet needs in the current standard of care for polycythemia vera (PV) and discusses the use of ruxolitinib in PV. The filming of this video was supported by Novartis....

ASH Highlights Videos

Dr Jean-Jacques Kiladjian summarises the unmet needs in the current standard of care for polycythemia vera (PV) and discusses the use of ruxolitinib in PV. The filming of this video was supported by Novartis. Speaker Disclosures: Novartis: advisory boards, institutional research grant; AOP...
Dr Shaji Kumar reviews the rationale for targeting the BCL-2 protein in multiple myeloma (MM) and the results of the recent phase I study of venetoclax. He also discusses selinexor combination therapy and the role of minimal residual disease in assessing response to therapies. FILMED AT THE...
Dr Mohamad Mohty discusses consolidation and maintenance therapy in multiple myeloma and whether these therapies can replace autologous stem cell transplantation (ASCT). FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Dr Mohamad Mohty gives his thoughts on innovative cellular therapy products and how they will enhance outcomes for haploidentical stem cell transplantation (haplo-SCT) patients. FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Dr Will Donnellan reviews the challenges in chimeric antigen receptor (CAR) T-cell therapy for acute myeloid leukemia (AML). He also gives us his thoughts on the lack of randomized trials for patients with refractory AML and discusses emerging antibody-based therapies. FILMED AT THE AMERICAN...
Dr Bruce Cheson reviews the current treatment landscape for non-Hodgkin lymphoma and discusses the results of the phase III GADOLIN study, comparing obinutuzumab plus bendamustine with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. FILMED AT THE AMERICAN...
Dr Naval Daver discusses the use of nivolimumab and ipilimumab in combination with azacitidine in myelodysplastic syndrome and acute myeloid leukemia. FILMED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING 2016, SAN DIEGO, CALIFORNIA, US
Dr Ian Flinn discusses the use of duvelisib in relapsed refractory indolent non-Hodgkin lymphoma and the findings of the DYNAMO study. He also discusses the results of the polatuzumab vendotin in combination with obinutuzumab study, presented at ASH 2016. FILMED AT THE AMERICAN SOCIETY OF...
Michele Baccarani - Filmed at ASH 2015, Orlando, CA: Michele Baccarani discusses the latest developments in CML.